Chemotherapy tolerance and continuity are prognostic for overall survival in patients with localized and advanced biliary tract cancer
Turkish Journal of Medical Sciences · 12.12.2025 · 55 (6) · 1445-1458
DOI: 10.55730/1300-0144.6102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 12.12.2025. Verfasst von Erman Akkuş und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/aim: Biliary tract cancers (BTC) are relatively rare and have a poor prognosis in both localized and metastatic settings. Clinical trials tend to include patients who can tolerate treatments; however, chemotherapy eligibility, patterns, and survival may differ in the real world. The present study provides a 5-year overview of chemotherapy eligibility, patterns, tolerance, and survival in patients with resected and advanced BTCs. Materials and methods: Included in the study were patients with resectable or advanced BTC (excluding ampullary cancers) diagnosed between 2019 and 2024. The demographic/clinical characteristics, chemotherapy eligibility, patterns, and survival outcomes of the patients were evaluated. Results: Of the 151 patients included in the study, 61 (40.7%) had resected BTC and 90 (59.3%) had advanced BTC. Among the patients with resected BTC, only 52.5% received adjuvant chemotherapy, 38.7% needed dose reductions, and 29% could not complete the planned cycles. Median recurrence-free survival and overall survival (OS) were 24.1 months (95% confidence interval (CI): 11.4–58.0) and 59 months (95% CI: 38.4–59) in patients with resected BTC, respectively, for all patients. In a multivariable analysis, only the number of adjuvant chemotherapy cycles was associated with OS [Hazard ratio (HR):0.63 (95% CI: 0.39–1.00), p=0.050]. Among the patients with advanced disease, 16.7% were not eligible for first-line chemotherapy, and 70.7% needed dose reduction. The median number of cycles was three (0-18); grade 3–4 adverse events were observed in 52% of the patients; and median progression-free survival and OS were 4.3 months (95% CI: 3.3–5.0) and 9.4 months (95% CI: 5.9–13.7) for all patients, respectively. Only 36.7% were able to receive second-line treatment. The number of first-line chemotherapy cycles [HR: 0.58 (95% CI: 0.45–0.76), p < 0.001]/discontinuation due to toxicity [HR: 3.26 (95% CI: 1.34–7.93), p = 0.009], cisplatin-gemcitabine regimen [HR: 0.10 (95% CI: 0.01–0.58), p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye.
- Cancer Research Institute, Ankara University, Ankara, Turkiye.
ORCID-Profile: Erman Akkuş, Pınar Kubilay Tolunay, Elif Berna Köksoy, Hatime Arzu Yaşar
Zitieren
APA
Akkuş, E., Kubilay Tolunay, P., Köksoy, E. B., & Yaşar, H. A. (2025). Chemotherapy tolerance and continuity are prognostic for overall survival in patients with localized and advanced biliary tract cancer. Turkish Journal of Medical Sciences, 55(6), 1445-1458. https://doi.org/10.55730/1300-0144.6102
Vancouver
Akkuş E, Kubilay Tolunay P, Köksoy EB, Yaşar HA. Chemotherapy tolerance and continuity are prognostic for overall survival in patients with localized and advanced biliary tract cancer. Turkish Journal of Medical Sciences. 2025;55(6):1445-1458. doi:10.55730/1300-0144.6102
BibTeX
@article{Akku2025,
author = {Akkuş, Erman and Kubilay Tolunay, Pınar and Köksoy, Elif Berna and Yaşar, Hatime Arzu},
title = {Chemotherapy tolerance and continuity are prognostic for overall survival in patients with localized and advanced biliary tract cancer},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {6},
pages = {1445--1458},
doi = {10.55730/1300-0144.6102}
}
EUVIMED